# Rosiglitazone to Reverse Metabolic Defects in Diabetes

> **NCT00094796** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 70 (—)

## Conditions studied

- Diabetes Mellitus, Type II
- Insulin Resistance

## Interventions

- **PROCEDURE:** Exercise cardiopulmonary metabolic testing
- **PROCEDURE:** Skeletal muscle biopsy
- **PROCEDURE:** Brachial artery reactivity testing

## Key facts

- **NCT ID:** NCT00094796
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10-20
- **Primary completion:** —
- **Final completion:** 2008-09-03
- **Target enrollment:** 70 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00094796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00094796, "Rosiglitazone to Reverse Metabolic Defects in Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00094796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*